Opendata, web and dolomites

NATURE-ETN SIGNED

Nucleic Acids for Future Gene Editing, Immunotherapy and Epigenetic Sequence Modification

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NATURE-ETN project word cloud

Explore the words cloud of the NATURE-ETN project. It provides you a very rough idea of what is the project "NATURE-ETN" about.

na    training    manipulation    engineering    scientific    chemists    breakthrough    therapies    disease    nas    culture    basic    discoveries    outstanding    smes    etn    despite    tools    skills    paradigm    epigenetic    deep    cas9    acid    nature    career    regarding    workshops    chemistry    combined    fellows    meet    base    industry    pioneering    editing    generation    medicine    questions    tech    limitations    translation    receive    combination    environment    immunotherapy    planning    cell    commercial    serious    leverage    undesired    gene    century    applicability    therapy    deletions    leaders    insertions    outcomes    crystallography    functioning    intersectoral    world    therapeutic    skillset    crispr    originating    treatment    mutations    expertise    biotech    excellence    genomics    immunotherapies    yield    today    boundaries    unrivalled    technologies    biomaterials    predicted    stage    off    extend    disciplinary    transferable    biologists    human    laboratories    sequencing    cells    business    materials    give    nucleic    quality    prolonged    cancer    21st    grow    disruptive    15    dna   

Project "NATURE-ETN" data sheet

The following table provides information about the project.

Coordinator
DUBLIN CITY UNIVERSITY 

Organization address
address: Glasnevin
city: DUBLIN
postcode: 9
website: www.dcu.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 4˙041˙816 €
 EC max contribution 4˙041˙816 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DUBLIN CITY UNIVERSITY IE (DUBLIN) coordinator 824˙052.00
2    THE UNIVERSITY OF READING UK (READING) participant 606˙345.00
3    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 505˙576.00
4    USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I. CZ (PRAHA 6) participant 469˙743.00
5    ATDBIO LIMITED UK (SOUTHAMPTON HAMPSHIRE) participant 303˙172.00
6    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 303˙172.00
7    ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS FR (PARIS CEDEX 05) participant 274˙802.00
8    NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING LIMITED IE (BLACKROCK DUBLIN) participant 274˙684.00
9    BASECLICK GMBH DE (NEURIED) participant 252˙788.00
10    UNIWERSYTET WARSZAWSKI PL (WARSZAWA) participant 227˙478.00

Map

 Project objective

Nucleic acid (NAs) therapies are predicted to yield major advances in the treatment of human disease and new approaches in NA design are required to extend the boundaries of today`s gene editing technologies, cancer immunotherapies, and epigenetic base manipulation tools. Current gene editing technologies involving CRISPR-Cas9, despite their wide applicability, have serious limitations involving off-target or prolonged effects that produce mutations, insertions, and deletions leading to undesired therapeutic outcomes. Questions also remain regarding the development and delivery of NAs for manipulation of T-cells, now seen as the new paradigm in cancer research. NATURE-ETN will meet this challenge by engineering new biomaterials and therapies to extend the boundaries of i.) gene editing technology, ii.) cancer immunotherapy, and iii.) epigenetic base manipulation. Our research programme involves world-leading chemists and biologists in combination with high-tech/biotech SMEs and industry partners. We will use our combined expertise in NA chemistry, DNA crystallography, materials chemistry, cell culture, and epigenetic sequencing to develop an outstanding multi-disciplinary environment were 15 Early Stage Researchers will receive unrivalled research training in the most exciting gene therapy research today. The intersectoral training provided will encompass scientific and transferable skills, an understanding of industry, and features targeted workshops in sequencing and genomics along with quality/business management and future career planning. NATURE-ETN will leverage breakthrough discoveries—some originating from our own laboratories—to provide training excellence to give our fellows a deep skillset in the translation of basic research into high functioning commercial NA biomaterials. NATURE-ETN will develop the next generation of pioneering scientific leaders in Europe where they will grow our commercial need for disruptive technologies in 21st century medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NATURE-ETN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NATURE-ETN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

AIMed (2020)

Antimicrobial Integrated Methodologies for orthopaedic applications

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More